Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped woul...
FILE PHOTO: The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann
The drug’s star fell in October when the Basel-based company announced it had failed a pair of trials in moderate asthmatic patients. Novartis chief drug developer John Tsai had continued to hold out hope that the trial failures in moderate patients were a fluke and that the drug would be more effective in patients hit harder by the respiratory disorder.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Swiss body considers ban on Swatch unit selling parts - Schweiz am WochenendeA Swatch unit that supplies parts to much of the watch market faces a possible s...
Consulte Mais informação »
Novartis to abandon development of asthma drug after trial failuresSwiss drugmaker Novartis is abandoning development of its drug fevipiprant in as...
Consulte Mais informação »
Tuberculosis kills more people than any other pathogenic illnessA quarter of the world's population has latent tuberculosis. Only 10% go on to develop symptoms
Consulte Mais informação »